References
- Aiello NM, Stanger BZ. Echoes of the embryo: using the developmental biology toolkit to study cancer. Dis Model Mech. 2016 Feb;9(2):105–114.
- Sell S, Nicolini A, Ferrari P, et al. Cancer: a problem of developmental biology; scientific evidence for reprogramming and differentiation therapy. Curr Drug Targets. 2016;17(10):1103–1110. DOI:https://doi.org/10.2174/1389450116666150907102717.
- Motofei IG.Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation.Semin Cancer Biol.2021 Oct 23; S1044-579X(21)00253–4. https://doi.org/10.1016/j.semcancer.2021.10.003.
- Motofei IG. Biology of cancer; from cellular cancerogenesis to supracellular evolution of malignant phenotype. Cancer Invest. 2018;36(5):309–317. DOI:https://doi.org/10.1080/07357907.2018.1477955.
- Napoli C, Giordano A, Casamassimi A, et al. Directed in vivo angiogenesis assay and the study of systemic neoangiogenesis in cancer. Int J Cancer. 2011 Apr 1;128(7):1505–1508.
- Huang T, Song X, Xu D, et al. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 2020 Jul 9;10(19):8721–8743.
- Lommerts JE, Bekkenk MW, Luiten RM. Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion. Expert Opin Drug Saf. 2021 Apr 26;20(8):883–888. DOI:https://doi.org/10.1080/14740338.2021.1915279.
- Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018 Dec;19(12):1579–1589.
- Khan S, Gerber DE. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review. Semin Cancer Biol. 2020 Aug;64:93–101.
- Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol. 2018 Jan;96(1):21–33.
- Rogado J, Sánchez-Torres JM, Romero-Laorden N, et al. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer. 2019 Mar;109:21–27.
- Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019 Jun;16(6):356–371.
- Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer. 2017;123(S11):2143–2153.
- Huang, PW , Chang, JW. Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomed J. 2019 Oct;42(5):299–306. doi:https://doi.org/10.1016/j.bj.2019.09.002
- Kerepesi C, Bakacs T, Moss RW, et al. Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies [published online ahead of print, 2020 Mar 9]. Cancer Immunol Immunother. 2020;69(5):683–687.
- Seliger B. Combinatorial approaches with checkpoint inhibitors to enhance anti-tumor immunity. Front Immunol. 2019;10:999.
- Rapisuwon S, Izar B, Batenchuk C, et al. Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):61. DOI:https://doi.org/10.1186/s40425-019-0533-0.
- Chat V, Ferguson R, Simpson D, et al. Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. Cancer Immunol Immunother. 2019;68(6):897–905. DOI:https://doi.org/10.1007/s00262-019-02318-8.
- Eisinger S, Sarhan D, Boura VF, et al. Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells. Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):32005–32016.
- Roberts K, Culleton V, Lwin Z, et al. Immune checkpoint inhibitors: navigating a new paradigm of treatment toxicities. Asia Pac J Clin Oncol. 2017;13(4):277–288. DOI:https://doi.org/10.1111/ajco.12698.
- Marin-Acevedo JA, Chirila RM, Dronca RS. Immune checkpoint inhibitor toxicities. Mayo Clin Proc. 2019;94(7):1321–1329.
- Hu W, Wang G, Wang Y, et al. Uncoupling therapeutic efficacy from immune-related adverse events in immune checkpoint blockade. iScience. 2020 Sep 20;23(10):101580.
- Haanen J, Ernstoff M, Wang Y, et al. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer. 2020 Jun;8(1):e000604. DOI:https://doi.org/10.1136/jitc-2020-000604.
- Bizzaro N, Antico A, Villalta D. Autoimmunity and gastric cancer. Int J Mol Sci. 2018 Jan 26;19(2):377.
- Baecklund E, Smedby KE, Sutton LA, et al. Lymphoma development in patients with autoimmune and inflammatory disorders–what are the driving forces? Semin Cancer Biol. 2014 Feb;24:61–70.
- Motofei IG. Malignant melanoma: autoimmunity and supracellular messaging as new therapeutic approaches. Curr Treat Options Oncol. 2019;20(6):45. DOI:https://doi.org/10.1007/s11864-019-0643-4.
- Motofei IG. Melanoma and autoimmunity: spontaneous regressions as a possible model for new therapeutic approaches. Melanoma Res. 2019;29(3):231–236. DOI:https://doi.org/10.1097/CMR.0000000000000573.
- Dick J, Lang N, Slynko A, et al. Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. Immunotherapy. 2016;8(9):1033–1044. DOI:https://doi.org/10.2217/imt-2016-0083.
- Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23(25):6043–6053. DOI:https://doi.org/10.1200/JCO.2005.06.205.
- June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med. 2017 May 5;23(5):540–547.
- Hussaini S, Chehade R, Boldt RG, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis. Cancer Treat Rev. 2021 Jan;92:102134.
- Zhong L, Wu Q, Chen F, et al. Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. Cancer Immunol Immunother. 2021 Sep;70(9):2559–2576. DOI:https://doi.org/10.1007/s00262-020-02803-5.
- Palmieri DJ, Carlino MS. Immune checkpoint inhibitor toxicity. Curr Oncol Rep. 2018;20(9):72.
- Swami U, Monga V, Bossler AD, et al. Durable clinical benefit in patients with advanced cutaneous melanoma after discontinuation of Anti-PD-1 therapies due to immune-related adverse events. J Oncol. 2019;2019:1856594.
- Darvin P, Toor SM, Sasidharan Nair V, et al. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1‐11. DOI:https://doi.org/10.1038/s12276-018-0191-1.
- Davis MP, Panikkar R. Checkpoint inhibitors, palliative care, or hospice. Curr Oncol Rep. 2018;20(1):2.
- Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S3–23.
- Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017 Jun 20;18(7):716–724.
- Kareva I. Immune suppression in pregnancy and cancer: parallels and insights. Transl Oncol. 2020 Jul;13(7):100759.
- Andor N, Maley CC, Ji HP. Genomic instability in cancer: teetering on the limit of tolerance. Cancer Res. 2017 May 1;77(9):2179–2185.
- Pan RY, Chung WH, Chu MT, et al. Recent development and clinical application of cancer vaccine: targeting neoantigens. J Immunol Res. 2018 Dec 19;2018:4325874. DOI:https://doi.org/10.1155/2018/4325874.
- Schietinger A, Philip M, Schreiber H. Specificity in cancer immunotherapy. Semin Immunol. 2008 Oct;20(5):276–285.
- Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol. 2013 Nov;31(11):999–1008.
- Yang JC. Toxicities associated with adoptive t-cell transfer for cancer. Cancer J. 2015 Nov-Dec;21(6):506–509.
- Yeh S, Karne NK, Kerkar SP, et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology. 2009;116(5):981–989.e1. DOI:https://doi.org/10.1016/j.ophtha.2008.12.004.
- Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015 Apr 3;348(6230):69–74.
- Yarchoan M, Johnson BA 3rd, Lutz ER, et al. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017 Apr;17(4):209–222. DOI:https://doi.org/10.1038/nrc.2016.154.
- Saleh R, Elkord E. Acquired resistance to cancer immunotherapy: role of tumor-mediated immunosuppression. Semin Cancer Biol. 2020 Oct;65:13–27.
- Pollock RE, Roth JA. Cancer-induced immunosuppression: implications for therapy? Semin Surg Oncol. 1989;5(6):414–419.
- Nagaraju GP, Malla RR, Basha R, et al. Contemporary clinical trials in pancreatic cancer immunotherapy targeting PD-1 and PD-L1. Semin Cancer Biol. 2021 Nov 11; S1044-579X(21)00270–4. DOI:https://doi.org/10.1016/j.semcancer.2021.11.003.
- Rubin LG. Bacterial colonization and infection resulting from multiplication of a single organism. Rev Infect Dis. 1987 May-Jun;9(3):488–493.
- Langman RE. The specificity of immunological reactions. Mol Immunol. 2000 Aug;37(10):555–561.
- Wang RF. Tumor antigens discovery: perspectives for cancer therapy. Mol Med. 1997;3(11):716–731.
- Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198(4):569–580. DOI:https://doi.org/10.1084/jem.20030590.
- Zhao J, Chen AX, Gartrell RD, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019 Mar;25(3):462–469. DOI:https://doi.org/10.1038/s41591-019-0349-y.
- Yaguchi T, Sumimoto H, Kudo-Saito C, et al. The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol. 2011 Mar;93(3):294–300. DOI:https://doi.org/10.1007/s12185-011-0799-6.
- Passarelli A, Tucci M, Mannavola F, et al. The metabolic milieu in melanoma: role of immune suppression by CD73/adenosine. Tumour Biol. 2019;42(4):1010428319837138. DOI:https://doi.org/10.1177/1010428319837138.
- Ge M, Hu Z, Chen X, et al. PCC0208018 exerts antitumor effects by activating effector T cells. Int J Immunopathol Pharmacol. 2019;33:2058738419843366.
- Dang N, Lin Y, Rutgeerts O, et al. Solid tumor-induced immune regulation alters the GvHD/GvT paradigm after allogenic bone marrow transplantation. Cancer Res. 2019;79(10):2709–2721. DOI:https://doi.org/10.1158/0008-5472.CAN-18-3143.
- Kim SH, Roszik J, Cho SN, et al. The COX2 effector microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma. Clin Cancer Res. 2019;25(5):1650–1663. DOI:https://doi.org/10.1158/1078-0432.CCR-18-1163.
- Shidal C, Singh NP, Nagarkatti P, et al. MicroRNA-92 expression in CD133+ melanoma stem cells regulates immunosuppression in the tumor microenvironment via integrin-dependent activation of TGF-β. Cancer Res. 2019; pii: canres.2659.2018. DOI:https://doi.org/10.1158/0008-5472.CAN-18-2659.
- Zhang Y, Bush X, Yan B, et al. Gemcitabine nanoparticles promote antitumor immunity against melanoma. Biomaterials. 2019;189:48–59.
- Kamran N, Li Y, Sierra M, et al. Melanoma induced immunosuppression is mediated by hematopoietic dysregulation. Oncoimmunology. 2017;7(3):e1408750. DOI:https://doi.org/10.1080/2162402X.2017.1408750.
- Di Virgilio F, Adinolfi E. Extracellular purines, purinergic receptors and tumor growth. Oncogene. 2017;36(3):293‐ 303.
- Tung KH, Ernstoff MS, Allen C, et al. A review of exosomes and their role in the tumor microenvironment and host-tumor “Macroenvironment”. J Immunol Sci. 2019;3(1):4–8. DOI:https://doi.org/10.29245/2578-3009/2019/1.1165.
- Adrián Cabestré F, Moreau P, Riteau B, et al. HLA-G expression in human melanoma cells: protection from NK cytolysis. J Reprod Immunol. 1999;43(2):183–193. DOI:https://doi.org/10.1016/S0165-0378(99)00037-6.
- Loustau M, Anna F, Dréan R, et al. HLA-G Neo-expression on tumors. Front Immunol. 2020 Aug 14;11:1685. DOI:https://doi.org/10.3389/fimmu.2020.01685.
- Elliott RL, Jiang XP, Phillips JT, et al. Human leukocyte antigen G expression in breast cancer: role in immunosuppression. Cancer Biother Radiopharm. 2011 Apr;26(2):153–157. DOI:https://doi.org/10.1089/cbr.2010.0924.
- Xu DP, Shi WW, Zhang TT, et al. Elevation of HLA-G-expressing DC-10 cells in patients with gastric cancer. Hum Immunol. 2016 Sep;77(9):800–804. DOI:https://doi.org/10.1016/j.humimm.2016.01.003.
- Antonia SJ, Vansteenkiste JF, Moon E. Immunotherapy: beyond Anti-PD-1 and Anti-PD-L1 Therapies. Am Soc Clin Oncol Educ Book. 2016;35(36):e450–8.
- Yang X, Lin Y, Shi Y, et al. FAP Promotes Immunosuppression by Cancer-Associated fibroblasts in the tumor microenvironment via STAT3-CCL2 Signaling. Cancer Res. 2016 Jul 15;76(14):4124–4135.
- Cheng N, Bai X, Shu Y, et al. Targeting tumor-associated macrophages as an antitumor strategy. Biochem Pharmacol. 2021 Jan;183:114354.
- Groth C, Hu X, Weber R, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2019 Jan;120(1):16–25. DOI:https://doi.org/10.1038/s41416-018-0333-1.
- Allard B, Allard D, Buisseret L, et al. The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. 2020 Oct;17(10):611–629. DOI:https://doi.org/10.1038/s41571-020-0382-2.
- Di Gennaro P, Gerlini G, Caporale R, et al. T regulatory cells mediate immunosuppresion by adenosine in peripheral blood, sentinel lymph node and TILs from melanoma patients. Cancer Lett. 2018;417:124‐ 130.
- Ohta A, Sitkovsky M. Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol. 2014 Jul 10;5:304. DOI:https://doi.org/10.3389/fimmu.2014.00304.
- Dong K, Gao ZW, Zhang HZ. The role of adenosinergic pathway in human autoimmune diseases. Immunol Res. 2016 Dec;64(5–6):1133–1141.
- Vigano S, Alatzoglou D, Irving M, et al. Targeting adenosine in cancer immunotherapy to enhance T-cell function. Front Immunol. 2019 Jun 6;10:925. DOI:https://doi.org/10.3389/fimmu.2019.00925.
- Vijayan D, Young A, Teng MWL, et al. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer. 2017 Dec;17(12):709–724. DOI:https://doi.org/10.1038/nrc.2017.86.
- Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018 Jun 18;6(1):57.
- Wuerfel FM, Huebner H, Häberle L, et al. HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment. Sci Rep. 2020 Sep 25;10(1):15750.
- González A, Rebmann V, LeMaoult J, et al. The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci. 2012 May-Jun;49(3):63–84. DOI:https://doi.org/10.3109/10408363.2012.677947.
- Ferreira LMR, Meissner TB, Tilburgs T, et al. HLA-G: at the Interface of Maternal-Fetal Tolerance. Trends Immunol. 2017 Apr;38(4):272–286. DOI:https://doi.org/10.1016/j.it.2017.01.009.
- Hunt JS, Petroff MG, McIntire RH, et al. HLA-G and immune tolerance in pregnancy. FASEB J. 2005 May;19(7):681–693. DOI:https://doi.org/10.1096/fj.04-2078rev.
- Yazdani N, Shekari Khaniani M, Bastami M, et al. HLA-G regulatory variants and haplotypes with susceptibility to recurrent pregnancy loss. Int J Immunogenet. 2018 Aug;45(4):181–189. DOI:https://doi.org/10.1111/iji.12364.
- Xu X, Zhou Y, Wei H. Roles of HLA-G in the Maternal-Fetal Immune Microenvironment. Front Immunol. 2020 Oct 22;11:592010. DOI:https://doi.org/10.3389/fimmu.2020.592010.
- Gautam S, Kumar U, Kumar M, et al. Association of HLA-G 3ʹUTR polymorphisms with soluble HLA-G levels and disease activity in patients with rheumatoid arthritis: a case-control study. Immunol Invest. 2020 Feb;49(1–2):88–105. DOI:https://doi.org/10.1080/08820139.2019.1657146.
- Ben Yahia H, Boujelbene N, Babay W, et al. Expression analysis of immune-regulatory molecules HLA-G, HLA-E and IDO in endometrial cancer. Hum Immunol. 2020 Jun;81(6):305–313. DOI:https://doi.org/10.1016/j.humimm.2020.03.008.
- Paul P, Rouas-Freiss N, Khalil-Daher I, et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4510–4515.
- Zidi I, Ben Amor N. HLA-G regulators in cancer medicine: an outline of key requirements. Tumour Biol. 2011 Dec;32(6):1071–1086.
- Krijgsman D, Roelands J, Hendrickx W, et al. HLA-G: a new immune checkpoint in cancer? Int J Mol Sci. 2020 Jun 25;21(12):4528.
- Zidi I, Ben Amor N. Nanoparticles targeting HLA-G for gene therapy in cancer. Med Oncol. 2012 Jun;29(2):1384–1390.
- Yan WH. HLA-G expression in cancers: potential role in diagnosis, prognosis and therapy. Endocr Metab Immune Disord Drug Targets. 2011 Mar;11(1):76–89.
- Wang S, Sun F, Li M, et al. The appropriate frequency and function of decidual Tim-3+CTLA-4+CD8+ T cells are important in maintaining normal pregnancy. Cell Death Dis. 2019 May 28;10(6):407.
- Meggyes M, Miko E, Szigeti B, et al. The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface. BMC Pregnancy Childbirth. 2019 Feb 19;19(1):74.
- Ding JL, Diao LH, Yin TL, et al. Aberrant expressions of endometrial Id3 and CTLA-4 are associated with unexplained repeated implantation failure and recurrent miscarriage. Am J Reprod Immunol. 2017 Aug;78(2):e12632. DOI:https://doi.org/10.1111/aji.12632.
- Li G, Lu C, Gao J, et al. Association between PD-1/PD-L1 and T regulate cells in early recurrent miscarriage. Int J Clin Exp Pathol. 2015 Jun 1;8(6):6512–6518.
- Bucheit AD, Hardy JT, Szender JB, et al. Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition. Melanoma Res. 2020 Aug;30(4):423–425. DOI:https://doi.org/10.1097/CMR.0000000000000657.
- Haanen JB, Robert C. Immune checkpoint inhibitors. Prog Tumor Res. 2015;42:55–66.
- Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014 Nov 27;515(7528):577–581.
- Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013 Dec;3(12):1355–1363. DOI:https://doi.org/10.1158/2159-8290.CD-13-0310.
- Jacobs JF, Idema AJ, Bol KF, et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol. 2009 Aug;11(4):394–402. DOI:https://doi.org/10.1215/15228517-2008-104.
- Mahoney KM, Shukla SA, Patsoukis N, et al. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunol Immunother. 2019;68(3):421‐ 432. DOI:https://doi.org/10.1007/s00262-018-2282-1.
- Dammeijer F, van Gulijk M, Mulder EE, et al. The PD-1/PD-L1-checkpoint restrains t cell immunity in tumor-draining lymph nodes. Cancer Cell. 2020 Nov 9;38(5):685–700.e8.
- Chaudhri A, Xiao Y, Klee AN, et al. PD-L1 Binds to B7-1 only in cis on the same cell surface. Cancer Immunol Res. 2018 Aug;6(8):921–929. DOI:https://doi.org/10.1158/2326-6066.CIR-17-0316.
- Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017 May 25;545(7655):495–499.
- Zhu Z, Zhang H, Chen B, et al. PD-L1-mediated immunosuppression in glioblastoma is associated with the infiltration and M2-polarization of tumor-associated macrophages. Front Immunol. 2020 Nov 30;11:588552. DOI:https://doi.org/10.3389/fimmu.2020.588552.
- Granier C, Karaki S, Roussel H, et al. Immunothérapie des cancers: rationnel et avancées récentes [Cancer immunotherapy: rational and recent breakthroughs]. Rev Med Interne. 2016 Oct;37(10):694–700. DOI:https://doi.org/10.1016/j.revmed.2016.05.023.
- Wilcox JA, Ramakrishna R, Magge R. Immunotherapy in Glioblastoma. World Neurosurg. 2018 Aug;116:518–528.
- Ngiow SF, Young A. Re-education of the tumor microenvironment with targeted therapies and immunotherapies. Front Immunol. 2020 Jul 28;11:1633. DOI:https://doi.org/10.3389/fimmu.2020.01633.
- Joshi S, Durden DL. Combinatorial approach to improve cancer immunotherapy: rational drug design strategy to simultaneously hit multiple targets to kill tumor cells and to activate the immune system. J Oncol. 2019;2019:5245034.
- Bräunlein E, Krackhardt AM. Tools to define the melanoma-associated immunopeptidome. Immunology. 2017 Dec;152(4):536–544.
- Cervinkova M, Kucerova P, Cizkova J. Spontaneous regression of malignant melanoma- is it based on the interplay between host immune system and melanoma antigens? Anticancer Drugs. 2017;28(8):819–830.
- Passarelli A, Mannavola F, Stucci LS, et al. Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget. 2017;8(62):106132–106142. DOI:https://doi.org/10.18632/oncotarget.22190.
- Behnia F, Zare M, Elojeimy S. Spontaneous regression of a metastatic melanoma pulmonary deposit following biopsy. Radiol Case Rep. 2018;13(3):580–582.
- Ong SF, Harden M, Irandoust S, et al. Spontaneous regression of pulmonary metastatic melanoma. Respirol Case Rep. 2015;4(1):7–9. DOI:https://doi.org/10.1002/rcr2.138.
- Pérez Ramírez S, Parra V, Avilés Izquierdo JA, et al. Metastatic melanoma with spontaneous regression, psoriasis and HLA-Cw6: case report and a hypothesis to explore. Tumori. 2014;100(4):144e–7e. DOI:https://doi.org/10.1177/1636.17932.
- Kucerova P, Cervinkova M. Spontaneous regression of tumour and the role of microbial infection—possibilities for cancer treatment. Anticancer Drugs. 2016;27(4):269–277.
- Motofei IG. Herpetic viruses and spontaneous recovery in melanoma. Med Hypotheses. 1996;47(2):85–88.
- Renno T, Lebecque S, Renard N, et al. What’s new in the field of cancer vaccines? Cell Mol Life Sci. 2003 Jul;60(7):1296–1310. DOI:https://doi.org/10.1007/s00018-003-2185-x.
- Saade Lemus P, Anderson K, Smith M, et al. Spontaneous regression of pancreatic cancer with liver metastases. BMJ Case Rep. 2019 May 31;12(5):e229619.
- Maire C, Vercambre-Darras S, Devos P, et al. Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort. J Eur Acad Dermatol Venereol. 2013 Jan;27(1):92–96. DOI:https://doi.org/10.1111/j.1468-3083.2011.04364.x.
- Chiang HC, Liao AT, Jan TR, et al. Gene-expression profiling to identify genes related to spontaneous tumor regression in a canine cancer model. Vet Immunol Immunopathol. 2013 Feb 15;151(3–4):207–216.
- Maio M. Melanoma as a model tumour for immuno-oncology. Ann Oncol. 2012 Sep;23(8):viii10–4.
- Ram M, Shoenfeld Y. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality? Ann N Y Acad Sci. 2007;1110(1):410–425.
- Byrne KT, Turk MJ. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget. 2011;2(9):684–694.
- Teulings HE, Overkamp M, Ceylan E, et al. Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. Br J Dermatol. 2013;168(1):162–171. DOI:https://doi.org/10.1111/bjd.12111.
- Paradisi A, Tabolli S, Didona B, et al. Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo. J Am Acad Dermatol. 2014;71(6):1110–1116. DOI:https://doi.org/10.1016/j.jaad.2014.07.050.
- Wajima T. Spontaneous regression of chronic lymphocytic leukemia and simultaneous development of autoimmune hemolytic anemia and autoimmune thrombocytopenia. Am J Hematol. 2000 Sep;65(1):88–89.
- Uohashi A, Imoto S, Matsui T, et al. Spontaneous regression of diffuse large-cell lymphoma associated with Hashimoto’s thyroiditis. Am J Hematol. 1996 Nov;53(3):201–202. DOI:https://doi.org/10.1002/(SICI)1096-8652(199611)53:3<201::AID-AJH10>3.0.CO;2-G.
- Ip YT, Pong WM, Kao SS, et al. Spontaneous complete regression of gastric large-cell neuroendocrine carcinoma: mediated by cytomegalovirus-induced cross-autoimmunity? Int J Surg Pathol. 2011 Jun;19(3):355–358. DOI:https://doi.org/10.1177/1066896911404412.
- Seremet T, Planken S, Schwarze JK, et al. Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma. Melanoma Res. 2019;29(1):85–88. DOI:https://doi.org/10.1097/CMR.0000000000000501.
- Chesney J, Imbert-Fernandez Y, Telang S, et al. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors. Melanoma Res. 2018;28(3):250–255. DOI:https://doi.org/10.1097/CMR.0000000000000444.
- Harrington K, Freeman DJ, Kelly B, et al. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019 Sep;18(9):689–706. DOI:https://doi.org/10.1038/s41573-019-0029-0.
- Sun L, Funchain P, Song JM, et al. Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. J Immunother Cancer. 2018;6(1):36. DOI:https://doi.org/10.1186/s40425-018-0337-7.
- Cavalcante L, Chowdhary A, Sosman JA, et al. Combining tumor vaccination and oncolytic viral approaches with checkpoint inhibitors: rationale, pre-clinical experience, and current clinical trials in malignant melanoma. Am J Clin Dermatol. 2018;19(5):657–670. DOI:https://doi.org/10.1007/s40257-018-0359-4.
- Hamid O, Ismail R, Puzanov I. Intratumoral Immunotherapy-Update 2019. Oncologist. 2020 Mar;25(3):e423–e438.
- Iglesias P, Ribero S, Barreiro A, et al. Induced vitiligo due to talimogene laherparepvec injection for metastatic melanoma associated with long-term complete response. Acta Derm Venereol. 2019;99(2):232–233. DOI:https://doi.org/10.2340/00015555-3061.
- Johnson DB, Puzanov I, Kelley MC. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy. 2015;7(6):611–619.
- Axelrod ML, Johnson DB. Balko JM emerging biomarkers for cancer immunotherapy in melanoma. Semin Cancer Biol. 2018;52(Pt 2):207–215.
- Yi M, Qin S, Zhao W, et al. The role of neoantigen in immune checkpoint blockade therapy. Exp Hematol Oncol. 2018;7(1):28. DOI:https://doi.org/10.1186/s40164-018-0120-y.
- Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23(35):8968–8977. DOI:https://doi.org/10.1200/JCO.2005.01.109.
- Bisschop C, Wind TT, Blank CU, et al. Association between pembrolizumab-related adverse events and treatment outcome in advanced melanoma: results from the dutch expanded access program. J Immunother. 2019;42(6):208–214.
- Zitouni NB, Arnault JP, Dadban A, et al. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. Melanoma Res. 2019;29(2):212–215. DOI:https://doi.org/10.1097/CMR.0000000000000536.
- Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100(14):8372–8377. DOI:https://doi.org/10.1073/pnas.1533209100.
- Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12(12):1005–1016. DOI:https://doi.org/10.1245/ASO.2005.03.536.
- de Moel EC, Rozeman EA, Kapiteijn EH, et al. Autoantibody development under treatment with immune-checkpoint inhibitors. Cancer Immunol Res. 2018;7(1):6–11. DOI:https://doi.org/10.1158/2326-6066.CIR-18-0245.
- Failla CM, Carbone ML, Fortes C, et al. Melanoma and vitiligo: in good company. Int J Mol Sci. 2019 Nov 15;20(22):5731.
- Klein O, Ebert LM, Nicholaou T, et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res. 2009;15(7):2507–2513. DOI:https://doi.org/10.1158/1078-0432.CCR-08-2424.
- Plaquevent M, Greliak A, Pinard C, et al. Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy. Melanoma Res. 2019;29(3):311–312. DOI:https://doi.org/10.1097/CMR.0000000000000555.
- Martín JM, Pinazo I, Monteagudo C, et al. Spontaneous regression of multiple melanocytic nevi after melanoma: report of 3 cases. Am J Dermatopathol. 2014;36(11):e183–8. DOI:https://doi.org/10.1097/DAD.0000000000000033.
- Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850–854. DOI:https://doi.org/10.1126/science.1076514.
- Yee C, Thompson JA, Roche P, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000 Dec 4;192(11):1637–1644.
- Du X, Tang F, Liu M, et al. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res. 2018 Apr;28(4):416–432. DOI:https://doi.org/10.1038/s41422-018-0011-0.
- Ingram JR, Blomberg OS, Rashidian M, et al. Anti-CTLA-4 therapy requires an Fc domain for efficacy. Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):3912–3917.
- Dahan R, Sega E, Engelhardt J, et al. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell. 2015 Sep 14;28(3):285–295.
- Arce Vargas F, Furness AJS, Litchfield K, et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell. 2018 Apr 9;33(4):649–663.e4.
- Simpson TR, Li F, Montalvo-Ortiz W, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013 Aug 26;210(9):1695–1710.
- Li X, Kimberly RP. Targeting the Fc receptor in autoimmune disease. Expert Opin Ther Targets. 2014 Mar;18(3):335–350.
- Zuercher AW, Spirig R, Baz Morelli A, et al. Next-generation Fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev. 2019 Oct;18(10):102366. DOI:https://doi.org/10.1016/j.autrev.2019.102366.
- Paluch C, Santos AM, Anzilotti C, et al. Immune checkpoints as therapeutic targets in autoimmunity. Front Immunol. 2018;9:2306. DOI:https://doi.org/10.3389/fimmu.2018.02306.
- Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016 Feb;54:139–148.
- Keenan TE, Burke KP, Van Allen EM. Genomic correlates of response to immune checkpoint blockade. Nat Med. 2019 Mar;25(3):389–402. doi:https://doi.org/10.1038/s41591-019-0382-x.
- Carretero R, Wang E, Rodriguez AI, et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer. 2012;131(2):387–395. DOI:https://doi.org/10.1002/ijc.26471.
- Bouwhuis MG, Gast A, Figl A, et al. Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis? Cancer Immunol Immunother. 2010;59(2):303–312. DOI:https://doi.org/10.1007/s00262-009-0751-2.
- Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008 Aug;224(1):166–182.
- Blenman KRM, Wang J, Cowper S, et al. Pathology of spontaneous and immunotherapy induced tumor regression in a murine model of melanoma. Pigment Cell Melanoma Res. 2019;32(3):448–457. DOI:https://doi.org/10.1111/pcmr.12769.
- Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382–386. DOI:https://doi.org/10.1038/s41586-018-0392-8.
- Schvartsman G, Taranto P, Glitza IC, et al. Management of metastatic cutaneous melanoma: updates in clinical practice. Ther Adv Med Oncol. 2019;11:1758835919851663.
- Phan GQ, Weber JS, Sondak VK. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. Ann Surg Oncol. 2008;15(11):3014–3021.
- Haanen JB, Robert C. Immune Checkpoint Inhibitors. Prog Tumor Res. 2015;42:55‐66.
- Zitvogel L, Perreault C, Finn OJ, et al. Beneficial autoimmunity improves cancer prognosis. Nat Rev Clin Oncol. 2021 Sep;18(9):591–602. DOI:https://doi.org/10.1038/s41571-021-00508-x.
- Eldershaw SA, Sansom DM, Narendran P. Expression and function of the autoimmune regulator (Aire) gene in non-thymic tissue. Clin Exp Immunol. 2011 Mar;163(3):296–308.
- Abramson J, Anderson G. Thymic epithelial cells. Annu Rev Immunol. 2017 Apr 26;35(1):85–118.
- Zhao B, Chang L, Fu H, et al. The role of autoimmune regulator (AIRE) in peripheral tolerance. J Immunol Res. 2018 Sep 4;2018:3930750. DOI:https://doi.org/10.1155/2018/3930750.
- Melo-Lima BL, Poras I, Passos GA, et al. The autoimmune regulator (AIRE) transactivates HLA-G gene expression in thymic epithelial cells. Immunology. 2019 Oct;158(2):121–135. DOI:https://doi.org/10.1111/imm.13099.
- Conteduca G, Indiveri F, Filaci G, et al. Beyond APECED: an update on the role of the autoimmune regulator gene (AIRE) in physiology and disease. Autoimmun Rev. 2018 Apr;17(4):325–330. DOI:https://doi.org/10.1016/j.autrev.2017.10.017.
- Perniola R. Expression of the autoimmune regulator gene and its relevance to the mechanisms of central and peripheral tolerance. Clin Dev Immunol. 2012;2012:207403.
- Bruserud Ø, Oftedal BE, Wolff AB, et al. AIRE-mutations and autoimmune disease. Curr Opin Immunol. 2016 Dec;43:8–15.
- Akirav EM, Ruddle NH, Herold KC. The role of AIRE in human autoimmune disease. Nat Rev Endocrinol. 2011 Jan;7(1):25–33.
- Zarek PE, Powell JD. Adenosine and anergy. Autoimmunity. 2007 Sep;40(6):425–432.
- Carosella ED, Rouas-Freiss N, Tronik-Le Roux D, et al. HLA-G: an immune checkpoint molecule. Adv Immunol. 2015;127:33–144.
- Cecati M, Emanuelli M, Giannubilo SR, et al. Contribution of adenosine-producing ectoenzymes to the mechanisms underlying the mitigation of maternal-fetal conflicts. J Biol Regul Homeost Agents. 2013 Apr-Jun;27(2):519–529.
- Gao ZW, Wang X, Zhang HZ, et al. The roles of adenosine deaminase in autoimmune diseases. Autoimmun Rev. 2021 Jan;20(1):102709. DOI:https://doi.org/10.1016/j.autrev.2020.102709.
- Magni G, Ceruti S. Adenosine signaling in autoimmune disorders. Pharmaceuticals (Basel). 2020 Sep 22;13(9):260.
- Rizzo R, Bortolotti D, Bolzani S, et al. HLA-G molecules in autoimmune diseases and infections. Front Immunol. 2014 Nov 18;5:592. DOI:https://doi.org/10.3389/fimmu.2014.00592.
- Verma N, Burns SO, Walker LSK, et al. Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations. Clin Exp Immunol. 2017 Oct;190(1):1–7. DOI:https://doi.org/10.1111/cei.12997.
- Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 2001 May;22(5):265–268.
- Bonnefoy N, Olive D, Vanhove B. Next generation of anti-immune checkpoints antibodies. Med Sci (Paris). 2019 Dec;35(12):966–974. DOI:https://doi.org/10.1051/medsci/2019193.
- Yu Y, Chen Z, Wang Y, et al. Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis. Int Immunopharmacol. 2021 Jul;96:107722. DOI:https://doi.org/10.1016/j.intimp.2021.107722.
- Rangachari M, Zhu C, Sakuishi K, et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion. Nat Med. 2012 Sep;18(9):1394–1400. DOI:https://doi.org/10.1038/nm.2871.
- Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019 Feb;51(2):202–206. DOI:https://doi.org/10.1038/s41588-018-0312-8.
- Schrock AB, Ouyang C, Sandhu J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019 Jul 1;30(7):1096–1103. DOI:https://doi.org/10.1093/annonc/mdz134.
- Buder-Bakhaya K, Hassel JC. Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-a review from the melanoma perspective and beyond. Front Immunol. 2018;9:1474.
- Jardim DL, Goodman A, de Melo Gagliato D, et al. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2021 Feb 8;39(2):154–173.
- Klempner SJ, Fabrizio D, Bane S, et al. Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence. Oncologist. 2020 Jan;25(1):e147–e159. DOI:https://doi.org/10.1634/theoncologist.2019-0244.
- Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018 Dec 27;6(1):157.
- Mooradian MJ, Sullivan RJ. What to do when anti-pd-1 therapy fails in patients with melanoma. Oncology (Williston Park). 2019;33(4):141–148.
- de La Rochefoucauld J, Noël N, Lambotte O. Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach [published online ahead of print, 2020 Mar 6]. Intern Emerg Med. 2020;15(4):587–598.
- Kadono T. Immune-related adverse events by immune checkpoint inhibitors. Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(2):83‐89.
- Triggianese P, Novelli L, Galdiero MR, et al. Immune checkpoint inhibitors-induced autoimmunity: the impact of gender. Autoimmun Rev. 2020 Aug;19(8):102590. DOI:https://doi.org/10.1016/j.autrev.2020.102590.
- Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019 Nov 15;7(1):306.
- Newton JM, Hanoteau A, Liu HC, et al. Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition. J Immunother Cancer. 2019 Aug 13;7(1):216.
- Weber R, Fleming V, Hu X, et al. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front Immunol. 2018;9:1310.
- Abdel-Wahab N, Shah M, Lopez-Olivo MA, et al. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018 Jan 16;168(2):121–130.
- Heinzerling L, de Toni EN, Schett G, et al. Checkpoint inhibitors. Dtsch Arztebl Int. 2019;116(8):119–126. DOI:https://doi.org/10.3238/arztebl.2019.0119.
- Li B, Chan HL, Chen P. Immune checkpoint inhibitors: basics and challenges. Curr Med Chem. 2019;26(17):3009‐ 3025.
- Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016 Oct 1;2(10):1346–1353. DOI:https://doi.org/10.1001/jamaoncol.2016.1051.
- Barshes NR, Goodpastor SE, Goss JA. Pharmacologic immunosuppression. Front Biosci. 2004 Jan 1;9(1–3):411–420. DOI:https://doi.org/10.2741/1249.
- Pan C, Liu H, Robins E, et al. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol. 2020 Apr 3;13(1):29.
- Shaashua L, Eckerling A, Israeli B, et al. Spontaneous regression of micro-metastases following primary tumor excision: a critical role for primary tumor secretome. BMC Biol. 2020 Nov 6;18(1):163.
- Kim MO, Kim SH, Oi N, et al. Embryonic stem-cell-preconditioned microenvironment induces loss of cancer cell properties in human melanoma cells. Pigment Cell Melanoma Res. 2011 Oct;24(5):922–931. DOI:https://doi.org/10.1111/j.1755-148X.2011.00891.x.
- Brodeur GM. Spontaneous regression of neuroblastoma. Cell Tissue Res. 2018 May;372(2):277–286.
- Ikram F, Ackermann S, Kahlert Y, et al. Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma. Mol Oncol. 2016 Feb;10(2):344–359. DOI:https://doi.org/10.1016/j.molonc.2015.10.020.
- Davis JE Jr, Kirk J, Ji Y, et al. Tumor dormancy and slow-cycling cancer cells. Adv Exp Med Biol. 2019;1164:199–206.
- Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy? Angiogenesis. 2017 May;20(2):185–204.
- Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science. 2013 Nov 8;342(6159):1234850.
- Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017 Feb 9;168(4):707–723.
- Wing JB, Tanaka A, Sakaguchi S. Human FOXP3+ regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity. 2019 Feb 19;50(2):302–316. DOI:https://doi.org/10.1016/j.immuni.2019.01.020.
- Sharabi A, Tsokos GC. T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nat Rev Rheumatol. 2020 Feb;16(2):100–112. DOI:https://doi.org/10.1038/s41584-019-0356-x.
- Kono M, Yoshida N, Tsokos GC. Metabolic control of T cells in autoimmunity. Curr Opin Rheumatol. 2020 Mar;32(2):192–199. DOI:https://doi.org/10.1097/BOR.0000000000000685.
- Kishton RJ, Sukumar M, Restifo NP. Metabolic regulation of t cell longevity and function in tumor immunotherapy. Cell Metab. 2017 Jul 5;26(1):94–109. DOI:https://doi.org/10.1016/j.cmet.2017.06.016.
- Palmer CS, Hussain T, Duette G, et al. Regulators of glucose metabolism in CD4+ and CD8+ T cells. Int Rev Immunol. 2016 Nov;35(6):477–488. DOI:https://doi.org/10.3109/08830185.2015.1082178.
- Uzun O, Senger AS, Gülmez S, et al. Evaluating the effect of tumor size on survival and its prognostic significance among gastric cancer patients. J Clin Invest Surg. 2020;5(2):76–82. Doi:https://doi.org/10.25083/2559.5555/5.2/76.82.
- Lu S, Stein JE, Rimm DL, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 2019 Aug 1;5(8):1195–1204. DOI:https://doi.org/10.1001/jamaoncol.2019.1549.
- Peng L, Wang Y, Liu F, et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol Immunother. 2020 Sep;69(9):1813–1822. DOI:https://doi.org/10.1007/s00262-020-02585-w.
- Valero C, Lee M, Hoen D, et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 2021 Feb 1;12(1):729. DOI:https://doi.org/10.1038/s41467-021-20935-9.
- Miricescu D, Diaconu CC, Stefani C, et al. The serine/threonine protein kinase (Akt)/ protein kinase b (pkb) signaling pathway in breast cancer. J Mind Med Sci. 2020;7(1):34–39. Doi:https://doi.org/10.22543/7674.71.P3439.
- Wantz M, Antonicelli F, Derancourt C, et al. Long-term survival and spontaneous tumor regression in stage IV melanoma: possible role of adrenalectomy and massive tumor antigen release. Ann Dermatol Venereol. 2010;137(6–7):464–467.
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. DOI:https://doi.org/10.1056/NEJMoa1504030.
- Hassel JC, Heinzerling L, Aberle J, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017;57:36–49.
- Gangi A, Zager JS. The safety of talimogene laherparepvec for the treatment of advanced melanoma. Expert Opin Drug Saf. 2017;16(2):265–269.
- Yu C, Liu X, Yang J, et al. Combination of immunotherapy with targeted therapy: theory and practice in metastatic melanoma. Front Immunol. 2019;10:990.
- Victor C T-S, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–377. DOI:https://doi.org/10.1038/nature14292.
- Paluch C, Santos AM, Anzilotti C, et al. Immune checkpoints as therapeutic targets in autoimmunity. Front Immunol. 2018;9:2306.
- Wrotek S, Brycht Ł, Wrotek W, et al. Fever as a factor contributing to long-term survival in a patient with metastatic melanoma: a case report. Complement Ther Med. 2018;38:7–10.
- Werner JM, Schweinsberg V, Schroeter M, et al. Successful treatment of myasthenia gravis following PD-1/CTLA-4 combination checkpoint blockade in a patient with metastatic melanoma. Front Oncol. 2019;9:84.
- Varadé J, Magadán S, González-Fernández Á. Human immunology and immunotherapy: main achievements and challenges. Cell Mol Immunol. 2021 Apr;18(4):805–828.